People Are Still Working on the Senolytic Peptide FOXO4-DRI
FOXO4-DRI, a senolytic peptide targeting the FOXO4–p53 interaction, remains an active preclinical focus with companies like Cleara Biotech and Numeric Biotech involved; recent studies report selective apoptosis of senescent endothelial cells and improved aortic function in aged and progeroid mice, while direct-to-consumer peptide availability and limited human data raise regulatory and evidence gaps.
Why it mattersFOXO4-DRI's mouse vascular efficacy implies investors should demand FDA-directed clinical development plans.